GRA worked in partnership with a European vaccine development company to lead an application for a £3 million SBRI contract funded by the UK’s Department of Health. The funds were intended for identification of a correlate of protection to enable phase III studies using clinical and preclinical studies relating to a Chikungunya vaccine.
GRA worked with the vaccine company to assemble a business case for the further development of a Chikungunya vaccine and justify how the funding could accelerate the program into phase III clinical trials. This case was put forward to the SBRI review panel. After a final interview panel, the application was confirmed as successful in June 2017. The project is being performed over a period of 3 year period. GRA successfully helped lead the application to raise £3 million in non-dilutional funding to develop the vaccine. GRA is also project managing the contract. Read the press release here.
Complete your details and we’ll send you regular updates via our newsletter.
Need to understand some element of the biopharma industry or looking for a particular template?